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Abstract 
Over the last decade, integrin αvβ3 has been studied with every single molecular imaging 
modality. Since no single modality is perfect and sufficient to obtain all the necessary infor-
mation for a particular question, combination of certain molecular imaging modalities can 
offer synergistic advantages over any modality alone. This review will focus on multimodality 
imaging of integrin αvβ3 expression, where the contrast agent used can be detected by two or 
more imaging modalities, such as combinations of PET and optical, SPECT and fluorescence, 
PET and MRI, SPECT and MRI, and lastly, MRI and fluorescence. Most of these agents are 
based on certain type(s) of nanoparticles. Contrast agents that can be detected by more than 
two imaging modalities are expected to emerge in the future and a PET/MRI/fluorescence 
agent will likely find the most future biomedical/clinical applications. Big strides have been 
made over the last decade for imaging integrin αvβ3 expression and several PET/SPECT probes 
have been tested in human studies. For dualmodality and multimodality imaging applications, a 
number of proof-of-principle studies have been reported which opened up many new avenues 
for  future  research.  The  next  decade  will  likely  witness  further  growth  and  continued 
prosperity of molecular imaging studies focusing on integrin αvβ3, which can eventually impact 
patient management. 
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Introduction 
The  field  of  molecular  imaging  has  flourished 
over the last decade, and perhaps the best example is 
integrin αvβ3-targeted imaging [1, 2]. Generally, mo-
lecular imaging techniques include positron emission 
tomography (PET), single-photon emission computed 
tomography (SPECT), molecular magnetic resonance 
imaging  (mMRI),  magnetic  resonance  spectroscopy 
(MRS), targeted ultrasound, optical bioluminescence, 
and optical fluorescence [3, 4]. Many hybrid systems 
that combine two or more of these imaging modalities 
are also commercially available and certain others are 
under active development [5-7].  
 Over  the  last  decade,  integrin  αvβ3  has  been 
studied with every single molecular imaging modal-
ity and many comprehensive reviews have been pub-
lished [1, 2, 8, 9]. As the key member of a family of cell 
adhesion  molecules,  integrin  αvβ3  binds  to  Argi-
nine-Glycine-Aspartic  acid  (RGD)-containing  com-Theranostics 2011, 1 
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ponents of the interstitial matrix such as vitronectin, 
fibronectin and thrombospondin [10]. Besides playing 
an important role in many normal physiological pro-
cesses [11, 12], integrin αvβ3 is also overexpressed in a 
number of tumor types such as melanoma, late stage 
glioblastoma, ovarian, breast, and prostate cancer [8, 
13, 14].  
 For optical imaging, RGD peptides or their mi-
metics have been conjugated with a variety of contrast 
agents such as near-infrared (NIR, 700 - 900 nm) flu-
orescent dyes [15-18], quantum dots (QDs) [19], and 
carbon  nanotubes  [20-22].  Contrast-enhanced  ultra-
sound imaging of integrin αvβ3 has been investigated 
with both microbubble-based agents [23, 24] and per-
fluorocarbon nanoparticles [25]. For mMRI of integrin 
αvβ3 expression,  Gd3+-containing paramagnetic  lipo-
somes  [26],  perfluorocarbon  nanoparticles  [27,  28], 
polymers [29], as well as iron oxide (IO)-based agents 
[30] have all been employed. The mainstay of molec-
ular  imaging  of  integrin  αvβ3  expression  is  with 
SPECT  and  PET  techniques,  which  has  been  exten-
sively investigated by many research groups around 
the  world  and  many  excellent  review  articles  are 
available [1, 31-33].  
 Among  all  molecular  imaging  modalities,  no 
single modality is perfect and sufficient to obtain all 
the  necessary  information  for  a  particular  question 
(Table  1).  For  example,  it  is  difficult  to  accurately 
quantify fluorescence signal in living subjects based 
on  fluorescence  imaging  alone,  particularly  in  deep 
tissues;  MRI  has  high  resolution  and  exquisite  soft 
tissue contrast yet it suffers from very low sensitivity; 
Ultrasound  is  more  widely  available  yet  targeting 
with microbubbles is mainly limited to the vascula-
ture; Radionuclide-based imaging techniques are very 
sensitive and highly quantitative but they have rela-
tively poor spatial resolution. Combination of certain 
molecular  imaging  modalities  can  offer  synergistic 
advantages over any single modality alone, and the 
“killer”  combination  would  depend  on  the  specific 
goal of a particular study. 
 
 
Table 1. A brief comparison of the various techniques for in vivo molecular imaging.  
Modality  Resolution  Sensitivity  Tissue Penetration  Quantitation capability  Cost  Clinical potential 
Fluorescence  medium  medium  poor  poor  $  low 
Ultrasound  medium  low  medium  poor  $  high 
MRI  high  low  good  poor  $$$  high 
SPECT  medium  high  good  good  $$  high 
PET  low  high  good  good  $$$  high 
 
 
 
 Multimodality imaging of integrin αvβ3 using a 
small  molecule-based  probe  is  very  challenging, 
sometimes impossible, due to the limited number of 
conjugation sites and the potential interference with 
its  receptor  binding  affinity.  Nonetheless,  this  ap-
proach has been undertaken and will be briefly illus-
trated in this review. On the other hand, nanoparticles 
have  large  surface  areas  where  multiple  functional 
moieties can be attached for multimodality molecular 
imaging  [34].  Nanotechnology,  an  interdisciplinary 
research  field  involving  physics,  chemistry,  engi-
neering, biology, and medicine, has great potential for 
future  personalized  treatment  of  diseases  including 
cancer  [35,  36].  Nanoparticles  are  typically  smaller 
than several hundred nanometers, comparable to the 
size  of  large  biological  molecules  such  as  enzymes, 
receptors, and antibodies. With sizes of about 2-4 or-
ders  of  magnitude  smaller  than  human  cells,  these 
nanoparticles  can  offer  unprecedented  interactions 
with biomolecules both on the surface of and inside 
the cells, which may revolutionize medical diagnosis 
and patient treatment. To date, the majority of mul-
timodality imaging studies of integrin αvβ3 expression 
involves certain type(s) of nanoparticles. 
 This review will focus on multimodality imag-
ing  of  integrin  αvβ3  expression,  where  the  contrast 
agent used can be detected by two or more imaging 
modalities. Comparing to the vast number of litera-
ture  reports  on  imaging  integrin  αvβ3  with  a  single 
modality, dualmodality or multimodality imaging of 
integrin αvβ3 is still in its infancy and there are only a 
small  number  of  reports  available  to  date.  Most  of 
these are proof-of-principle studies and there is still 
ample space for improvement in the future.  
Dualmodality PET/optical imaging of integ-
rin αvβ3  
 PET has been widely used in the clinic for stag-
ing  and  evaluating  many  types  of  cancer  [37].  The 
recently  developed  PET/CT  scanner,  already  being 
used on a routine basis in clinical oncology, greatly Theranostics 2011, 1 
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aids in the localization of regions of increased activity 
on PET [5, 38]. The combination of PET and fluores-
cence  imaging,  although  not  widely  clinically  rele-
vant,  can  provide  complimentary  information  in 
small animal models where light penetration is less of 
an issue. 
 Over the past decade, QDs have become one of 
the fastest growing areas of research in nanotechnol-
ogy [39-41]. For in vitro applications, these wonderful 
semiconductor fluorescent nanoparticles can be used 
in  place  of  traditional  organic  fluorescent  dyes  in 
virtually any system, outperforming organic dyes in 
the majority of cases. In vivo targeted tumor imaging 
with  biocompatible  QDs  has  also  been  achieved  in 
mouse models [19, 42, 43]. However, due to the diffi-
culty  in  quantifying  the  fluorescence  signal  in  vivo 
and many other technical challenges which remain to 
be solved, in vivo imaging of QDs is mostly qualita-
tive or semi-quantitative [39, 40]. Development of a 
dualmodality agent containing both an NIR QD and a 
PET isotope will allow for sensitive, accurate assess-
ment  of  the  pharmacokinetics  and  tumor  targeting 
efficacy of NIR QDs by PET, which may greatly facil-
itate  future  translation  of  QDs  into  clinical  applica-
tions.  
 We  reported  a  QD-based  probe  for  both  NIR 
fluorescence (NIRF) and PET imaging of integrin αvβ3 
expression [44]. Cyclic RGD peptides and DOTA (i.e. 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra  acidic 
acid) chelators were conjugated to a QD (maximum 
emission:  705  nm)  for  integrin  αvβ3-targeted, 
dualmodality PET/NIRF imaging of tumors in living 
mouse after 64Cu-labeling (Figure 1). Using this agent, 
we quantitatively evaluated the tumor targeting effi-
cacy. Moreover, this PET/NIRF probe can confer suf-
ficient  tumor  contrast  detectable  by  PET  at  much 
lower  concentration  than  that  required  for  in  vivo 
NIRF imaging [19], thus significantly reduces the po-
tential toxicity of cadmium-based QDs and may facil-
itate  future  biomedical  applications  [45,  46].  Histo-
logical  examination  revealed  that  the  agent  targets 
primarily  the  tumor  vasculature  via  RGD-integrin 
αvβ3  interaction  with  little  extravasation.  Taken  to-
gether, combining PET and NIRF imaging overcomes 
the  tissue  penetration  limitation  of  NIRF  imaging, 
allowing for quantitative in vivo targeted imaging in 
deep tissue. Such information will be crucial for fluo-
rescence-guided  surgery  through  sensitive,  specific, 
and real-time intra-operative visualization of the mo-
lecular features of normal and diseased processes.  
 Single-walled  carbon  nanotubes  (SWNTs)  ex-
hibit unique size, shape and physical properties that 
make  them  promising  materials  for  biologi-
cal/biomedical applications [22, 47, 48]. We investi-
gated  the  biodistribution  of  64Cu-labeled  SWNTs  in 
mice  by  PET,  ex  vivo  biodistribution,  and  Raman 
spectroscopy [49]. These SWNTs were highly stable in 
vivo and the surface polyethylene glycol (PEG) chain 
length could significantly  affect  their blood concen-
tration  and  biodistribution.  Effectively  PEGylated 
SWNTs  exhibit  relatively  long  circulation  half-life 
(about 2 h) and low uptake by the reticuloendothelial 
system  (RES).  Efficient  targeting  of  integrin 
αvβ3-positive  tumor  in  mice  was  achieved  with 
SWNTs coated with PEG chains linked to cyclic RGD 
peptides [49]. Most importantly, the intrinsic Raman 
signatures of SWNTs were used to directly probe the 
presence of SWNTs in mice tissues and confirm the 
radionuclide-based imaging results.  
 Radiolabeled  nanoparticles  represent  a  new 
class  of  probes  which  has  enormous  potential  for 
clinical applications. Different from other molecular 
imaging modalities where typically the nanoparticle 
itself is detected, radionuclide-based imaging detects 
the radiolabel rather than the nanoparticle. The na-
noparticle distribution is measured indirectly by as-
sessing the localization of the radionuclide, which can 
provide quantitative measurement of the tumor tar-
geting efficacy and pharmacokinetics only if the radi-
olabel  on  the  nanoparticle  is  stable  enough  under 
physiological conditions. However, dissociation of the 
radionuclide  (typically  metal)  from  the  chelator, 
and/or the radionuclide-containing polymer coating 
from  the  nanoparticle,  may  occur  which  can  cause 
significant  difference  between  the  nanoparticle  dis-
tribution  and  the  radionuclide  distribution.  Direct 
measurement of the nanoparticle itself, as well as rig-
orous validation of the stability of the radiolabel on 
the nanoparticle, should always be carried out to ob-
tain more reliable experimental results.  
 Recently,  directed  evolution  was  employed  to 
engineer knottin peptides that bind to various integ-
rins with high affinity [50]. To evaluate these peptides 
as  molecular  imaging  agents,  Cy5.5  or  DOTA  was 
site-specifically conjugated to their N termini for PET 
and fluorescence imaging of integrin αvβ3 in a U87MG 
human glioblastoma model [51]. Both NIRF and PET 
imaging showed that integrin binding affinity played 
an important role in the tumor uptake of knottin pep-
tides, where high-affinity knottin peptides had higher 
tumor uptake than the low-affinity knottin peptides. 
Although only one image tag can be attached to each 
knottin peptide, this study did demonstrate the po-
tential of these knottin peptides as a platform for po-
tential  multimodality  imaging  of  integrin  αvβ3  ex-
pression  where  different  image  tags  can  be  readily 
incorporated,  using  similar  chemistry,  for  different 
applications.  Theranostics 2011, 1 
 
http://www.thno.org 
138 
 In another recent report, ferritin nanocages were 
loaded with RGD peptides, Cy5.5 and 64Cu ferritin for 
integrin αvβ3-targeted PET/NIRF imaging [52]. Unlike 
traditional  conjugation  methods,  such  a  loading 
strategy minimizes the interference among different 
docked motifs and enables accurate control over the 
composition of the final conjugates, which may have 
implications  for  future  construction  of  multimodal 
imaging probes and nanoparticles-based theranostics. 
 
 
 
Figure 1. Dualmodality imaging of integrin αvβ3 on tumor vasculature with PET and fluorescence. A. A schematic structure 
of the dualmodality PET/NIRF probe. B. Fluorescence (after injection of QD-RGD) and coronal PET (after injection of 
64Cu-DOTA-QD-RGD) images of integrin αvβ3-positive U87MG tumor-bearing mice. Arrowheads indicate the tumors. C. 
Excellent overlay between CD31 and QD fluorescence, as well as between murine β3 and QD fluorescence, confirmed that 
DOTA-QD-RGD mainly targeted integrin αvβ3 on the tumor vasculature. Adapted from [44]. 
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Dualmodality imaging of integrin αvβ3 with 
SPECT and fluorescence 
 A  RGD  peptide  was  labeled  with  111In  and 
IRDye800 (maximum emission: 800 nm) for gamma 
scintigraphy and continuous-wave imaging of integ-
rin αvβ3-positive M21 melanoma xenografts, respec-
tively [53]. Twenty-four hours after administration of 
the agent at a dose equivalent to 90 μCi of 111In and 5 
nmol of IRDye800, whole-body gamma scintigraphy 
and optical imaging was conducted. It was found that 
while the target-to-background ratios of gamma scin-
tigraphy and optical imaging were similar for super-
ficial regions-of-interest, consistent with the origin of 
gamma  and  NIRF  signal  from  a  common  targeted 
agent,  the  signal-to-noise  ratio  (SNR)  was  signifi-
cantly higher for optical than radionuclide imaging. 
Analysis  of  SNR  versus  contrast  also  showed  that 
optical  imaging  had  greater  sensitivity  for  subcuta-
neous  tumor  targets.  However,  such  an  advantage 
quickly  diminishes  when  the  tissue  of  interest  gets 
deeper under the skin (> a few mm). Since fluores-
cence-mediated  tomography  is  still  not  a  mature 
technology [54, 55], accurate comparison between the 
two  modalities  was  not  feasible.  Nonetheless,  this 
proof-of-principle  study  demonstrated  for  the  first 
time the direct comparison of optical and planar ra-
dionuclide  imaging  for  superficial  and  sub-surface 
tumors. 
 In a follow-up study, the same probe was used 
for non-invasive detection of αvβ3-positive tumors in 
living  mice  with  both  optical  imaging  and  gamma 
scintigraphy [56]. Similar as what was reported pre-
viously,  optical  imaging  provided  better  resolution 
and more sensitive detection of the superficial lesions 
while gamma scintigraphy allowed for more sensitive 
detection of deeper structures. The major drawback of 
this SPECT/NIRF agent is that comparing to the size 
of the monomeric RGD peptide, the  111In-DTPA (i.e. 
diethylene triamine pentaacetic acid) complex and the 
fluorescent dye are both relatively bulky and can sig-
nificantly affect receptor binding. The reason why the 
imaging  studies  were  carried  out  at  24  hours  after 
injection  for  such  a  low  molecular  weight  agent, 
which usually gets cleared from the circulation and 
non-targeted  organs  within  minutes  or  hours,  was 
also unclear. A radioisotope with  a shorter half-life 
should  be  more  suitable  for  such  small  mole-
cule-based agent, which can significantly reduce the 
unnecessary  radiation  exposure  to  non-targeted  or-
gans.  
 To image the expression pattern of tumor integ-
rin αvβ3 through a multimodality imaging paradigm, 
a  RGD  peptide  analogue  (termed  “LS308”)  bearing 
both DOTA and a lipophilic NIRF dye (cypate) was 
constructed [57]. In vivo distribution of  111In-labeled 
LS308 in tumor-bearing mice was studied by fluores-
cence, bioluminescence (the tumor cells  were trans-
fected  with  luciferase),  planar  gamma,  and  SPECT 
imaging,  which  revealed  that  LS308  selectively  ac-
cumulated  in  integrin  αvβ3-positve  tumors  in  a  re-
ceptor-specific  manner and  could be  non-invasively 
visualized by various imaging modalities.  
 The reports described above were primarily fo-
cused on cancer. Although integrin αvβ3 is one of the 
key players in tumor angiogenesis and metastasis, it is 
also  important  in  many  other  angiogenesis-related 
diseases  such  as  inflammation  [58],  myocardial  in-
farction  (MI)  [59,  60],  atherosclerosis  [61],  among 
others [11, 12]. One recent study evaluated interstitial 
alterations in myocardial remodeling using a radio-
labeled  Cy5.5-RGD  peptide  (termed  “CRIP”)  that 
targets myofibroblasts [62]. The rationale of this study 
was that since collagen deposition and interstitial fi-
brosis  contribute  to  cardiac  remodeling  and  heart 
failure after MI, evaluation of myofibroblastic prolif-
eration should provide indirect evidence of the extent 
of  fibrosis.  99mTc-labeled  CRIP  was  injected  in  mice 
after coronary artery occlusion. Maximum CRIP up-
take was observed in the infarct area and peaked at 
about 2 weeks after surgery, which was histologically 
traced to myofibroblasts (Figure 2). More importantly, 
the experimental findings from both SPECT and flu-
orescence  imaging  corroborated  quite  well.  It  was 
suggested that this strategy, if proven clinically feasi-
ble,  would  help  identify  post-MI  patients  likely  to 
develop heart failure. 
Dualmodality imaging of integrin αvβ3 with 
PET and MRI 
 Accurate localization of PET probe uptake, even 
with PET/CT, can be very difficult in some cases due 
to  the  absence  of  identifiable  anatomical  structures, 
particularly in the abdomen [63, 64]. Combination of 
PET/MR can have many synergistic effects. In addi-
tion  to  the  exceptional  soft  tissue  contrast  of  MRI, 
highly accurate image registration can offer the pos-
sibility of using the MR image to correct for PET par-
tial volume effect and aid in PET image reconstruc-
tion. Moreover, PET/MR has greatly reduced radia-
tion  exposure  compared  with  PET/CT.  Prototype 
PET/MR systems have been implemented for small 
animal  imaging  and  preliminary  data  for  human 
studies  have  also  been  presented  [7,  65].  PET/MR, 
acquired  in  one  measurement,  has  the  potential  to 
become  the  imaging  modality  of  choice  for  various 
clinical  applications  such  as  neurological  studies, 
certain types of cancer, stroke, and the emerging field Theranostics 2011, 1 
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of cell-based therapy. The future of PET/MR scanners 
will  greatly  benefit  from  the  development  of 
dualmodality PET/MR imaging agents.  
 
 
Figure 2. Dualmodality imaging of integrin αvβ3 with SPECT and fluorescence. A. A RGD peptide is conjugated to both 
Cy5.5 and a chelating agent for radiolabeling with 
99mTc. B. After intravenous administration of the probe, localization of the 
Cy5.5 fluorescence (red) was observed in the infarct and peri-infarct zones in live animals at 2 weeks post-myocardial 
infarction (MI). A whole mouse slice also demonstrated myocardial uptake of the probe (square). C. Ex vivo images of the 
explanted hearts in control and post-MI animals after probe injection. Intense uptake was seen in 2-week post-MI animal. 
Adapted from [62]. 
 
 
 An  IO-based  probe  for  PET/MR  imaging  of 
tumor integrin αvβ3 expression has been reported [66]. 
Poly(aspartic acid)-coated IO nanoparticles (PASP-IO) 
were  prepared  and  the  surface  amino  groups  were 
coupled to cyclic RGD peptides for integrin αvβ3 tar-
geting  and  DOTA  chelators  for  PET  imaging  (after 
labeling with 64Cu), respectively. The PASP-IO nano-
particle had a core size of 5-7 nm with a hydrody-
namic diameter of ~40 nm. Based on PET imaging, the 
tumor  accumulation  of  64Cu-labeled  RGD-PASP-IO 
peaked  at  about  4  h  post-injection  while  the 
non-targeted  particle,  64Cu-DOTA-IO,  had  signifi-
cantly  lower  tumor  uptake  (Figure  3).  Blocking  ex-
periment  with  unconjugated  RGD  peptides  signifi-
cantly reduced the tumor uptake of the dualmodality 
agent, thus demonstrating receptor specificity in vivo. Theranostics 2011, 1 
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T2-weighted MRI corroborated the PET findings. Af-
ter in vivo PET and MRI scans, the animals were sac-
rificed and Prussian blue staining of the tumor tissue 
confirmed  integrin  αvβ3  specific  delivery  of  the 
RGD-PASP-IO  nanoparticles.  Similar  as  most  other 
nanoparticle-based imaging agents [67, 68], the RES 
uptake of this probe was also quite prominent. Over-
all, good correlation between the in vitro, in vivo and 
ex  vivo  assays  demonstrated  that  the  non-invasive 
imaging results accurately reflected the probe biodis-
tribution. This study represents the first example of in 
vivo dualmodality PET/MR imaging using a single 
agent.  
 
 
Figure 3. An IO nanoparticle-based dualmodality PET/MR agent. A. A schematic illustration of the dualmodality probe. The 
DOTA chelator enables PET imaging after 
64Cu-labeling. B. Coronal PET and T2-weighted MR images of tumor-bearing mice 
at 4 h after injection of 
64Cu-labeled RGD-PASP-IO, PASP-IO, and RGD-PASP-IO mixed with unconjugated RGD peptides 
(denoted as “Block”). Prussian blue staining of the U87MG tumor (integrin αvβ3-positive) tissue slices after scanning is also 
shown, where blue spots indicate the presence of IO nanoparticles. Adapted from [66]. Theranostics 2011, 1 
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Dualmodality imaging of integrin αvβ3 with 
SPECT and MRI  
 One recent study focused on the development of 
a  dualmodality,  integrin  αvβ3-targeted,  nanoparti-
cle-based imaging agent that affords sensitive nuclear 
detection  in  conjunction  with  high-resolution  MR 
characterization of tumor angiogenesis [69], with the 
ultimate goal of improving patient risk-benefit strati-
fication. New Zealand white rabbits bearing Vx2 tu-
mors  received  99mTc-labeled,  integrin  αvβ3-targeted 
nanoparticles  at  different  doses  and  were  imaged 
with  both  planar  gamma  camera  imaging  and 
SPECT/CT. MR sensitivity was incorporated into the 
nanoparticles  by  inclusion  of  lipophilic  Gd-chelates 
into the outer phospholipid layer. It was found that 
the tumor-to-muscle contrast ratio, after injection of 
the  nanoparticle,  was  dose-dependent  and  recep-
tor-specific.  More  importantly,  the  use  of 
99mTc-labeled targeted nanoparticles produced a clear 
neovasculature  signal  from  the  tumor  that  was  de-
tected with SPECT/CT. MRI and 3D mapping of an-
giogenesis in the small tumor revealed an asymmet-
rically  distributed,  patchy  neovasculature  along  the 
periphery of the tumor. It was suggested that these 
nanoparticles can afford highly sensitive and specific 
localization of tumor angiogenesis, which can be fur-
ther  characterized  with  high-resolution  MR  neovas-
cular  mapping  to  predict  responsiveness  to  an-
ti-angiogenic therapies. 
Dualmodality imaging of integrin αvβ3 with 
MRI and fluorescence 
 Among  all  the  dualmodality  imaging  agents 
reported  to  date,  combination  of  MRI  and  fluores-
cence  was  studied  the  most  extensively.  These 
dualmodality agents can be generally categorized into 
the  following  subtypes:  chemically  linking 
Gd-chelates  to  fluorescent  dyes  [70,  71],  liposomes 
containing Gd-chelates and fluorescent dyes [72, 73], 
QD-based agents [74-77], and paramagnetic nanopar-
ticles  containing  fluorescent  moieties  [78-86].  Being 
perhaps the most studied molecular target for imag-
ing  applications,  it  is  no  surprise  that  integrin  αvβ3 
was  also  the  target  of  interest  for  many  of  the 
dualmodality MR/fluorescence agents (Figure 4).  
 
 
Figure 4. Various approaches have been undertaken to construct dualmodality MR/fluorescence agents for imaging of 
integrin αvβ3 expression. A. An agent that contains a RGD peptide, Gd-DTPA, and a fluorescent dye. B. A PAMAM den-
drimer that contains a RGD peptide, Gd-DTPA, and a fluorescent dye. C. PEGylated paramagnetic and fluorescent lipo-
somes containing RGD peptides as the targeting ligand. D. A QD encapsulated in a paramagnetic micelle with multiple 
covalently linked RGD peptides. E. A SPIO nanoparticle conjugated with both a fluorescent dye and RGD peptides. Theranostics 2011, 1 
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 In one study, native chemical ligation was em-
ployed to synthesize an agent that contained a RGD 
peptide,  Gd-DTPA,  and  a  fluorescent  dye  Oregon 
Green 488 [87]. However, in vitro and in vivo behav-
ior of this agent has not been investigated. Due to the 
very low sensitivity of Gd-based MRI, such composi-
tion is not suitable for in vivo applications. Recently, 
polyamidoamine  (PAMAM)  dendrimers  covalently 
modified with RGD peptides were constructed [88]. 
Fluorescent dyes for optical imaging and chelates for 
Gd-based  MRI,  respectively,  were  subsequently  ap-
pended  to  create  the  dualmodality  imaging  agents. 
Fluorescence  microscopy  revealed  selective  binding 
of the resulting RGD peptide-bearing dendrimer with 
empty  chelates  to  integrin  αvβ3-expressing  cells, 
which  was  reduced  after  Gd  complexation.  In  vivo 
tissue distribution of this agent in tumor-bearing mice 
showed mostly renal and RES accumulation, with a 
moderate tumor-to-blood ratio. 
 Liposomes (usually more than 100 nm in diam-
eter)  can  accommodate  multiple  copies  of  Gd  and 
multiple copies of the targeting ligand, which can not 
only result in signal amplification but also in target 
specificity  [89].  PEGylated  paramagnetic  and  fluo-
rescent liposomes carrying RGD peptides have been 
studied  for  in  vivo  tumor  imaging  [90].  Both 
RGD-conjugated liposomes and RAD (a control pep-
tide which does not bind to integrin αvβ3)-conjugated 
liposomes gave enhanced T1-weighted MR contrast. 
Using ex vivo fluorescence microscopy, it was found 
that RGD-conjugated liposomes were specifically as-
sociated with the activated tumor endothelium while 
RAD-conjugated  liposomes  were  mostly  located  in 
the extravascular compartment. This family of lipidic 
vehicles may potentially be used to deliver therapeu-
tic  agents,  thus  forming  multifunctional  nanoplat-
forms  which  can  integrate  both  therapeutic  compo-
nents and multimodality imaging.  
Many  nanoparticle-based  agents  suffer  from 
poor tumor-to-background ratio due to the prolonged 
presence of contrast agent present in the blood pool 
[91-93].  In  a  recent  study,  the  target-to-background 
ratio of one MR/fluorescence agent was increased by 
the  use  of  “avidin  chase”,  which  allowed  rapid 
clearance  of  non-bound  paramagnetic 
RGD-containing liposomes from the circulation [94]. 
Mice  bearing  melanoma  tumors  received 
RGD-functionalized or untargeted biotinylated lipo-
somes, which was followed by avidin infusion or no 
infusion.  It  was  reported  that  besides  tar-
get-associated contrast agent, the circulating contrast 
agent  also  contributed  significantly  to  the  contrast 
enhancement.  Further,  ex  vivo  fluorescence  micros-
copy  confirmed  association  of  the  RGD-containing 
liposomes to tumor endothelial cells both with and 
without  avidin  infusion,  whereas  biotinylated  lipo-
somes  which  do  not  contain  RGD  peptides  were 
predominantly found within the vessel lumen. 
 QD encapsulated in a paramagnetic micelle with 
multiple  covalently  linked  RGD  peptides  was  con-
structed  [77].  The  integrin  αvβ3  specificity  was  as-
sessed  and  confirmed  on  cultured  endothelial  cells. 
However, in vivo targeted imaging of this agent has 
not been achieved with either MRI or optical imaging. 
Silica particles have quite favorable biocompatibility, 
which may be significantly improved by appropriate 
surface modification [95, 96]. In one study, silica na-
noparticles carrying a QD in the center and multiple 
RGD-peptides on the surface were reported [97]. Spe-
cific uptake of the nanoparticle by endothelial cells in 
vitro  was  demonstrated  with  both  fluorescence  mi-
croscopy  and  MRI.  In  another  report,  a 
RGD-containing nanoparticle, with a blood half-life of 
3 h, was found to be able to escape from the vascula-
ture over its long circulation time and target integrin 
αvβ3 expressed on tumor cells [98]. Recently, the use of 
a  QD-based  nanoparticle  for  both  optical  and  MRI 
detection of tumor angiogenesis was described [99]. 
Upon intravenous injection into tumor-bearing mice, 
intravital microscopy allowed the detection of angio-
genically activated endothelium at cellular resolution 
with a small scanning window and limited penetra-
tion depth, whereas MRI was used to visualize angi-
ogenesis at anatomical resolution throughout the en-
tire tumor. In another study, IO nanoparticles coated 
with  amphiphilic  triblock  copolymers  were  conju-
gated with a NIRF dye and cyclic RGD peptides for 
integrin αvβ3 targeting [100]. Successful tumor hom-
ing in vivo was achieved in a subcutaneous U87MG 
glioblastoma  xenograft  model  with  both  MRI  and 
NIRF imaging. 
Summary and future perspectives 
 Most  of  the  dualmodality  imaging  agents  re-
ported so far are based on certain nanoparticles. The 
use  of  molecularly  targeted  nanoparticles  affords 
many  advantages  over  conventional  small  mole-
cule-based  approaches  for  integrin  αvβ3  imaging. 
First,  hundreds,  thousands,  or  even  more  imaging 
labels, or a combination of labels for different imaging 
modalities, can  be attached to a  single  nanoparticle 
which can lead to dramatic signal amplification. Se-
cond, multiple, potentially different, targeting ligands 
on  the  nanoparticle  can  provide  enhanced  integrin 
αvβ3 binding affinity/specificity. Third, the ability to 
integrate various means to bypass biological barriers Theranostics 2011, 1 
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will give enhanced targeting efficacy. Ultimately, the 
combination  of  different  targeting  ligands,  imaging 
labels, therapeutic drugs, and many other agents may 
allow for effective and controlled delivery of thera-
peutic agents in patients which can be non-invasively 
and  quantitatively  monitored  in  real  time.  Several 
barriers  exist  for  in  vivo  applications  in  preclinical 
animal models and future clinical translation of such 
multifunctional/multimodality nanoparticles, among 
which  are  the  biocompatibility,  in  vivo  kinetics,  in-
tegrin αvβ3 targeting efficacy, acute and chronic tox-
icity,  the  ability  to  escape  the  RES,  and 
cost-effectiveness.  
 One intriguing phenomenon is that the above-
mentioned  agents  are  mostly  for  dualmodality 
MR/fluorescence imaging applications, which is due 
to the exploding interest in IO nanoparticles and QDs 
over the last decade [41, 101]. However, most of these 
agents are not ideal/suitable for in vivo applications. 
More importantly, it is debatable whether combina-
tion  of  MRI  and  fluorescence  is  the  most  optimal 
dualmodality  approach  since  neither  modality  is 
quantitative. Molecular MRI is still in its infancy [102] 
and dualmodality imaging including MRI is relatively 
rare. Nanoparticles usually suffer from poor extrava-
sation when compared to small molecules or proteins 
[19, 44, 103]. Thus, the feasible targets reachable by 
targeted nanoparticles (the basis of most dualmodal-
ity  imaging  agents)  will  be  mostly  vascula-
ture-related, as the overall hydrodynamic diameter of 
these nanoparticles with surface polymer coating and 
targeting ligands are quite large (typically > 20 nm in 
diameter) which prohibits extravasation. As a matter 
of fact, this is one of the major reasons why integrin 
αvβ3 is the most popular target for dualmodality mo-
lecular imaging, since it is expressed not only on tu-
mor  cells  but  also  on  many  sprouting  vessels  thus 
extravasation is not required to achieve tumor con-
trast.  
 Newly  developed  nanoparticles  with  smaller 
sizes  (preferably  <  10  nm  in  diameter)  and  longer 
circulation half-lives (at least a few hours) may allow 
for extravasation from the leaky tumor vasculature to 
a certain extent. Since the major disadvantage of MRI 
is its inherent low sensitivity, which is exacerbated by 
almost  exclusively  vasculature  targeting,  future  de-
velopment of novel contrast agents with the capability 
of targeting the tumor cells in addition to the vascu-
lature may dramatically increase the MR signal and 
facilitate the biomedical applications of dualmodality 
imaging agents targeting integrin αvβ3. 
 Dualmodality contrast agents that combine ra-
dionuclide-based imaging (PET or SPECT), which is 
very  sensitive  and  highly  quantitative,  and 
non-radionuclide based approaches, for example op-
tical imaging which can significantly facilitate ex vivo 
validation of the in vivo data or MRI which can pro-
vide high resolution anatomical information, should 
be of particular interest for future biomedical appli-
cations. PET has significantly higher sensitivity than 
SPECT  [104].  Therefore,  PET/fluorescence  and 
PET/MR contrast agents deserve much research effort 
in the near future. One scenario where a dualmodality 
approach will be particularly useful is that an initial 
whole body PET scan can be carried out to identify the 
location of tumor(s), and the optical component can 
subsequently  help  pinpointing  the  position  during 
surgery for tumor resection.  
 Contrast  agents  that  can  be  detected  by  more 
than  two  imaging  modalities  are  also  expected  to 
emerge in the future. Although various combinations 
of  different  imaging  modalities  can  serve  different 
purposes depending on the study design, we envision 
that a PET/MR/fluorescence agent will find the most 
future  biomedical/clinical  applications  since  such  a 
combination  provides  extremely  high  sensitivity 
(PET),  quantitation  capability  (PET),  excellent  ana-
tomical information and soft tissue contrast (MRI), as 
well as a means for ex vivo validation (optical) which 
itself can also be useful for highly sensitive imaging in 
certain sites of the human body. Recently, one such 
multimodality probe was reported [105]. However, no 
targeting ligand was incorporated and in vivo imag-
ing was only achieved with PET (but not with optical 
imaging or MRI) due to its much better sensitivity and 
tissue penetration.  
 Big strides have been made over the last decade 
for  imaging  integrin  αvβ3  expression  and  several 
PET/SPECT probes have been tested in human stud-
ies  [106-109].  For  dualmodality  and  multimodality 
imaging applications, many critical proof-of-principle 
studies have been reported which opened up many 
new avenues for future research. We expect that the 
next decade will witness further growth and contin-
ued prosperity of molecular imaging studies focusing 
on  integrin  αvβ3,  which  we  believe  will  eventually 
make significant impact on clinical patient manage-
ment.  
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